CRL
Charles River Laboratories International, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth +11.1% ·
share flow +11.8% ·
net new positions +10.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 140 | -1 | 45.53M | $10.31B | +6 | −6 |
| Q1 2026 | 143 | -7 | 45.52M | $7.86B | +6 | −14 |
| Q4 2025 | 150 | +3 | 43.69M | $8.72B | +4 | — |
| Q3 2025 | 22 | 0 | 23.18M | $3.62B | +1 | −2 |
| Q2 2025 | 20 | +2 | 21.36M | $3.24B | +4 | −2 |
| Q1 2025 | 15 | 0 | 9.57M | $1.44B | +1 | −1 |
| Q4 2024 | 15 | +1 | 9.65M | $1.78B | +1 | — |
| Q3 2024 | 13 | -1 | 6.67M | $1.31B | — | −1 |
| Q2 2024 | 14 | — | 3.92M | $810.09M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 5.81M | — | $881.82M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 2 | Wellington Management ✦ | 3.77M | -12.1% | $571.69M | 0.1% | ▼ Trim | 5 | SEC ↗ ×8 |
| 3 | BlackRock ✦ (passive) | 3.66M | — | $554.74M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 4 | State Street Global Advisors ✦ (passive) | 1.86M | -2.3% | $282.03M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.23M | -2.5% | $186.60M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 6 | Harris Associates (Oakmark) ✦ | 1.16M | New | $176.45M | 0.3% | New | 1 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 607.02K | New | $92.10M | 0.1% | New | 1 | SEC ↗ ×2 |
| 8 | Arrowstreet Capital ✦ | 578.61K | +63.6% | $87.79M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 564.59K | +100.2% | $85.67M | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 10 | Millennium Management ✦ | 507.32K | +580.9% | $76.98M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 11 | Norges Bank ✦ (passive) | 507.16K | +15.8% | $76.95M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 12 | PRIMECAP Management ✦ | 270.60K | -0.8% | $41.06M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | Gotham Asset Management ✦ | 269.16K | +73.9% | $40.84M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 14 | Point72 Asset Management ✦ | 236.41K | New | $35.87M | 0.1% | New | 1 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 93.67K | -42.6% | $14.21M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | Fidelity (FMR) ✦ | 78.32K | — | $11.88M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 17 | T. Rowe Price ✦ | 74.47K | -2.0% | $11.30M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 18 | Adage Capital Partners ✦ | 45.00K | New | $6.83M | 0.0% | New | 1 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 26.76K | +329.1% | $4.02M | 0.0% | ▲ Add | 5 | SEC ↗ ×5 |
| 20 | Marshall Wace ✦ | 14.07K | -62.9% | $2.14M | 0.0% | ▼ Trim | 5 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Harris Associates (Oakmark) | $176.45M | 0.3% |
| D. E. Shaw & Co. | $92.10M | 0.1% |
| Point72 Asset Management | $35.87M | 0.1% |
| Adage Capital Partners | $6.83M | 0.0% |
Exited
| Fisher Asset Management | $38.42M | was 0.0% |
| Baillie Gifford | $7,375 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 555 holders, 56.84M shares, $9.32B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer · EVP & Chief Financial… · 10 sh @ 297.43 · $2,974
Open-market sales (S)
Officer · 981 sh · $302,580
Director · 33.56K sh · $10.07M
Officer · 2.04K sh · $599,711
Director · 573 sh · $163,443
Officer, Director · 6.50K sh · $1.82M
Officer · 3.71K sh · $1.04M
Director · 28.73K sh · $7.90M
Officer · 620 sh · $163,643
Officer · 482 sh · $127,812
Officer · 404 sh · $104,446
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology